Patent · US Active

System and method for bone loss assay

US10557857B1 · kind B1 · utility

0Cited by
7References
2Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 23, 2016
Grant dateFeb 11, 2020
Priority date—
Expiry dateNov 8, 2037

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/108
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

Disclosed are embodiments of a lateral flow test strip (LFTS) platform which measure osteocalcin (OC) and deoxypyridinoline (Dpd) in saliva to identify early indications of bone loss and minimize bone fracture risk associated with osteoporosis. The OC assay embodiments are based on the experimentally identified optimal markers which exhibit selectivity with very low false positives, and sensitivity relevant to clinical requirements. A prospective clinical study sampling of 20 patients demonstrated excellent correlation of OC in saliva with bone mineral density (BMD). Salivary OC and Dpd levels were validated with a standard commercial ELISA kit against serum (OC) and urine (Dpd).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.